초록 close

저자 등은 gefitinib 투약 중 발생한 급성호흡곤란으로 사망한 2 예를 경험하였기에 이를 보고하는 바이다.


Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. We describe two non-small cell lung cancer patients who developed acute respiratory failure after gefitinib, and suggest that clinicians take extreme caution when deciding to treat patients with gefitinib. (Tuberc Respir Dis 2007; 62: 144-148)